157 related articles for article (PubMed ID: 22886297)
21. Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness.
Hambley TW; Battle AR; Deacon GB; Lawrenz ET; Fallon GD; Gatehouse BM; Webster LK; Rainone S
J Inorg Biochem; 1999 Oct; 77(1-2):3-12. PubMed ID: 10626347
[TBL] [Abstract][Full Text] [Related]
22. Unusual dimeric chemical structure for a carboplatin analogue as a potential anticancer complex.
Xie M; Liu W; Lou L; Chen X; Ye Q; Yu Y; Chang Q; Hou S
Inorg Chem; 2010 Jul; 49(13):5792-4. PubMed ID: 20515022
[TBL] [Abstract][Full Text] [Related]
23. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
24. Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential.
Leal J; Santos L; Fernández-Aroca DM; Cuevas JV; Martínez MA; Massaguer A; Jalón FA; Ruiz-Hidalgo MJ; Sánchez-Prieto R; Rodríguez AM; Castañeda G; Durá G; Carrión MC; Barrabés S; Manzano BR
J Inorg Biochem; 2021 May; 218():111403. PubMed ID: 33730639
[TBL] [Abstract][Full Text] [Related]
25. Novel endothall-containing platinum(IV) complexes: synthesis, characterization, and cytotoxic activity.
Reithofer MR; Valiahdi SM; Galanski M; Jakupec MA; Arion VB; Keppler BK
Chem Biodivers; 2008 Oct; 5(10):2160-2170. PubMed ID: 18972539
[TBL] [Abstract][Full Text] [Related]
26. Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.
Zhang JZ; Wexselblatt E; Hambley TW; Gibson D
Chem Commun (Camb); 2012 Jan; 48(6):847-9. PubMed ID: 22124352
[TBL] [Abstract][Full Text] [Related]
27. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
28. Oxidative halogenation of cisplatin and carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(IV) prodrugs.
Johnstone TC; Alexander SM; Wilson JJ; Lippard SJ
Dalton Trans; 2015 Jan; 44(1):119-29. PubMed ID: 25367395
[TBL] [Abstract][Full Text] [Related]
29. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
30. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
[TBL] [Abstract][Full Text] [Related]
31. Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.
Savino S; Gandin V; Hoeschele JD; Marzano C; Natile G; Margiotta N
Dalton Trans; 2018 May; 47(21):7144-7158. PubMed ID: 29766157
[TBL] [Abstract][Full Text] [Related]
32. Novel oximato-bridged platinum(II) di- and trimer(s): synthetic, structural, and in vitro anticancer activity studies.
Scaffidi-Domianello YY; Legin AA; Jakupec MA; Roller A; Kukushkin VY; Galanski MS; Keppler BK
Inorg Chem; 2012 Jul; 51(13):7153-63. PubMed ID: 22691006
[TBL] [Abstract][Full Text] [Related]
33. Not the usual suspect - an unexpected organometallic product during the synthesis of cytotoxic platinum(II) complexes.
Maier T; Wutschitz J; Gajic N; Hejl M; Cseh K; Mai S; Jakupec MA; Galanski MS; Keppler BK
Dalton Trans; 2023 Nov; 52(44):16326-16335. PubMed ID: 37855721
[TBL] [Abstract][Full Text] [Related]
34. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.
Navas F; Chocarro-Calvo A; Iglesias-Hernández P; Fernández-García P; Morales V; García-Martínez JM; Sanz R; De la Vieja A; García-Jiménez C; García-Muñoz RA
J Med Chem; 2024 Apr; 67(8):6410-6424. PubMed ID: 38592014
[TBL] [Abstract][Full Text] [Related]
35. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
Chen S; Yao H; Zhou Q; Tse MK; Gunawan YF; Zhu G
Inorg Chem; 2020 Aug; 59(16):11676-11687. PubMed ID: 32799457
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, characterization, and cytotoxic activity of novel potentially pH-sensitive nonclassical platinum(II) complexes featuring 1,3-dihydroxyacetone oxime ligands.
Scaffidi-Domianello YY; Legin AA; Jakupec MA; Arion VB; Kukushkin VY; Galanski MS; Keppler BK
Inorg Chem; 2011 Nov; 50(21):10673-81. PubMed ID: 21951170
[TBL] [Abstract][Full Text] [Related]
37. Antitumor Platinium(IV) Prodrugs: A Systematic Computational Exploration of Their Reduction Mechanism by l-Ascorbic Acid.
Dabbish E; Ponte F; Russo N; Sicilia E
Inorg Chem; 2019 Mar; 58(6):3851-3860. PubMed ID: 30843385
[TBL] [Abstract][Full Text] [Related]
38. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
[TBL] [Abstract][Full Text] [Related]
39. Thermoresponsive carboplatin-releasing prodrugs.
McAdam AD; Batchelor LK; Romano-deGea J; Vasilyev D; Dyson PJ
J Inorg Biochem; 2024 May; 254():112505. PubMed ID: 38377623
[TBL] [Abstract][Full Text] [Related]
40. trans-Platinum(iv) pro-drugs that exhibit unusual resistance to reduction by endogenous reductants and blood serum but are rapidly activated inside cells:
Chen CKJ; Kappen P; Gibson D; Hambley TW
Dalton Trans; 2020 Jun; 49(23):7722-7736. PubMed ID: 32469362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
